Form 4: Fairmount Funds Director Receives Apogee Therapeutics Option

Director Tomas Kiselak of Fairmount Funds Management was granted an option to purchase 7,657 shares of Apogee Therapeutics common stock.

Summary

• Tomas Kiselak, a director at Apogee Therapeutics and Managing Member of Fairmount Funds Management, received a stock option grant for 7,657 shares.
• The option has an exercise price of $85.00 per share.
• The grant date is June 9, 2026, with an expiration date of June 9, 2036.
• The options vest on the one-year anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of future share issuance upon exercise of options.

Risks

• Vesting is subject to continued service, creating potential turnover risk if the director departs before June 9, 2027.

Future Outlook

The options vest in one year, indicating a long-term retention strategy for the director.

Management Comments

• Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of the investment vehicles managed by Fairmount.
• Mr. Kiselak disclaims beneficial ownership of the option and underlying common stock.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between leadership and shareholders, particularly for companies in the development stage.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is consistent with standard corporate governance practices for NASDAQ-listed biotech firms.
• The one-year vesting schedule is a common retention mechanism for board members in the industry.

Corporate Governance

Related Party Transactions

• Mr. Kiselak holds the option for investment vehicles managed by Fairmount Funds Management LLC and is obligated to transfer proceeds to said funds.

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options on June 9, 2027.

Key Dates

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Trading, Stock Options, Fairmount Funds